As the ligand of EGFR, EREG is commonly upregulated in cancer types, such as non-small cell lung cancer, breast cancer, gastric cancer, head and neck cancer, ovarian cancer, colorectal cancer, brain cancer, and bladder cancer (20). Here, EREG is linked to gastric cancer.